Company Profile

Ensign Pharmaceutical Inc
Profile last edited on: 5/25/2022      CAGE: 8DDM3      UEI: E9R1Z4LWYHV8

Business Identifier: New treatment for arthritis
Year Founded
2019
First Award
2020
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6457 Frances Street Suite 100
Omaha, NE 68106
   (617) 733-5264
   N/A
   www.ensignpharmaceutical.com
Location: Single
Congr. District: 02
County: Douglas

Public Profile

With strong ties to University of Nebraska Medical School and the College of Pharmacy, the start-up Ensign Pharmaceutical is structured around development to full use-condition of novel pharmaceutical products designed to free patients from pain without damaging side-effects. Also of primary interest to the firm's principals is addressing development of more effective healing of musculoskeletal disorders and inflammatory diseases. Ensign's personnel have established working relationships with the rheumatology and orthopedic programs at University of Nebraska and the Nebraska Arthritis Outcomes Research Center - the latter having the personnel and expertise to conduct the clinical trials. As a firm, the work of Ensign Pharmaceutical is anchored in on a novel formulation injectable liquid - designated ProGel. When injected,ProGel transforms into a gel-like substance as it reaches body temperature. In gel format, the product remains longer the affected area - effectively concentrating the pharmaceutical payload where it needs to be. Other pharmaceuticals can be combined with ProGel, making it a “platform technology.” : effectively providing localized and sustained delivery of a variety of therapeutic agents to treat a broad spectrum of clinical conditions.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 NIH $1,933,011
Project Title: Progel Technology for Better Management of Osteoarthritis Pain

Key People / Management

  Steven Goldring

  Gang Zhao

Company News

There are no news available.